DARIOHEALTH CORP
DRIONASDAQTrading Snapshot
- Day Range
- $398.36 – $409.80
- 52-Week Range
- $5.84 – $17.74
- Volume
- $4.41B
- Avg Volume
- $4.98B
- Shares Outstanding
- 7.3M
- Next Earnings
- Nov 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $22M
- Last Q Revenue
- $5M
- P/E Ratio
- 9.6
- P/S Ratio
- 2.3x
- EPS (TTM)
- $7.25
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +22.8%
Why Investors Own DRIO
- ✓High-growth profile — revenue up +25.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
DARIOHEALTH CORP
DRIO
StockOtter · stockotter.spaceAbout DARIOHEALTH CORP
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
DARIOHEALTH CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift DRIO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
DARIOHEALTH CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.